Comparison
Melatonin vs Memantine (Namenda)
Melatonin
Pineal hormone regulating circadian rhythm. Low doses (0.3-1mg) often outperform higher doses for sleep.
Memantine (Namenda)
Prescription NMDA receptor antagonist for moderate-to-severe Alzheimer's disease. Reduces glutamate excitotoxicity while preserving normal signaling.
| Field | Melatonin | Memantine (Namenda) |
|---|---|---|
| Category | neuroprotective | neuroprotective |
| Dose range | 0.3–3mg | 5–20mg |
| Half-life | 1h | 70h |
| Onset | 30min | 180min |
| Evidence | EVIDENCEA | EVIDENCEA |
| Safety | ●●●●● | ●●●●○ |
| Legal (US) | USOTC | USRx |
| PubMed refs | 28000 | 4200 |
The comparison in plain English
Auto-generated from dataMelatonin and Memantine (Namenda) are both in the neuroprotective category respectively. Melatonin Pineal hormone regulating circadian rhythm. Memantine (Namenda) Prescription NMDA receptor antagonist for moderate-to-severe Alzheimer's disease.
Bottom line
Melatonin (evidence A, safety 5/5) matches the evidence base of Memantine (Namenda) (evidence A, safety 4/5). Melatonin has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose Melatonin if
Melatonin is the better fit when your goal aligns with its mechanism (Endogenous hormone produced by the pineal gland in response to darkness, signalling the circadian sleep window) and the dose range (0.3–3mg) suits your protocol. Half-life is 1h.
Choose Memantine (Namenda) if
Memantine (Namenda) is the better fit when your goal aligns with its mechanism (Uncompetitive NMDA receptor antagonist — blocks the NMDA channel only when it's pathologically over-activated, sparing normal signaling) and the dose range (5–20mg) suits your protocol. Half-life is 70h.